Terms: = Thyroid cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2
560 results:
1. RPGRIP1L as a new biomarker for prognosis and tumor immune of breast cancer.
Yi J; Liu L; Chen Y; Ding T; Fan P; Yu J; Zeng J
FASEB J; 2024 May; 38(9):e23624. PubMed ID: 38747001
[TBL] [Abstract] [Full Text] [Related]
2. Radiological Features for Predicting the Status of CD8-Positive Lymphocytes in her2 Positive Breast cancer.
Fan Y; Li X; Zhong P; Guo H; Han D; Tian W; Fang J
Balkan Med J; 2024 May; 41(3):213-221. PubMed ID: 38700366
[TBL] [Abstract] [Full Text] [Related]
3. Absolute lymphocyte count and neutrophil-to-lymphocyte ratio as predictors of CDK 4/6 inhibitor efficacy in advanced breast cancer.
Nakamoto S; Shien T; Iwamoto T; Kubo S; Yamamoto M; Yamashita T; Kuwahara C; Ikeda M
Sci Rep; 2024 Apr; 14(1):9869. PubMed ID: 38684839
[TBL] [Abstract] [Full Text] [Related]
4. DNA Methylation-Regulated HOXC8's Role in her2-Positive Breast cancer Function and its Contribution to Herceptin Resistance.
Xie X; Tang S; Yu Z
Discov Med; 2024 Mar; 36(182):559-570. PubMed ID: 38531796
[TBL] [Abstract] [Full Text] [Related]
5. Construction and validation of nomogram for the cancer-specific mortality for her2-positive breast cancer patients.
Wu N
Medicine (Baltimore); 2024 Mar; 103(11):e37330. PubMed ID: 38489717
[TBL] [Abstract] [Full Text] [Related]
6. External beam radiation therapy for recurrent or residual thyroid cancer: What is the best treatment time and the best candidate for long-term local disease control?
Cavalcante LBCP; Treistman N; Gonzalez FMTT; Fernandes PIW; Alves Junior PAG; Andrade FA; Ferreira EN; Brito TF; Pane A; Corbo R; Erlich F; Bulzico DA; Vaisman F
Head Neck; 2024 Jun; 46(6):1340-1350. PubMed ID: 38445804
[TBL] [Abstract] [Full Text] [Related]
7. Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast cancer Society Clinical Practice Guidelines.
Hattori M; Honma N; Nagai S; Narui K; Shigechi T; Ozaki Y; Yoshida M; Sakatani T; Sasaki E; Tanabe Y; Tsurutani J; Takano T; Saji S; Masuda S; Horii R; Tsuda H; Yamaguchi R; Toyama T; Yamauchi C; Toi M; Yamamoto Y
Breast Cancer; 2024 May; 31(3):335-339. PubMed ID: 38433181
[TBL] [Abstract] [Full Text] [Related]
8. [Clinical characteristics and prognostic factors of breast cancer patients with tumor deposits in the ipsilateral axillary region].
Xiao JJ; Huang ML; Yan CJ; Ling R; Wei HL
Zhonghua Zhong Liu Za Zhi; 2024 Feb; 46(2):146-154. PubMed ID: 38418189
[No Abstract] [Full Text] [Related]
9. Isocitrate dehydrogenase 2 regulates the proliferation of triple-negative breast cancer through the ferroptosis pathway.
Zhang C; Zhou Y; Chen T; Bhushan S; Sun S; Zhang P; Yang Y
Sci Rep; 2024 Feb; 14(1):4732. PubMed ID: 38413708
[TBL] [Abstract] [Full Text] [Related]
10. Identifying prognostic biomarkers for palbociclib add-on therapy in fulvestrant-resistant breast cancer using cell-free DNA sequencing.
Takeshita T; Iwamoto T; Niikura N; Watanabe K; Kikawa Y; Kobayashi K; Iwakuma N; Okamura T; Tada H; Ozaki S; Okuno T; Toh U; Yamamoto Y; Tsuneizumi M; Ishiguro H; Masuda N; Saji S
ESMO Open; 2024 Apr; 9(4):102385. PubMed ID: 38387111
[TBL] [Abstract] [Full Text] [Related]
11.
Li F; Wu Y; Shi Y; Liu X; Xie Y; Liu S
Acta Biochim Biophys Sin (Shanghai); 2024 Mar; 56(3):462-473. PubMed ID: 38379418
[TBL] [Abstract] [Full Text] [Related]
12. miRNA-449c-5p regulates the JAK-STAT pathway in inhibiting cell proliferation and invasion in human breast cancer cells by targeting erbb2.
Li L; Zhang Y; Yang K; Liu W; Zhou Z; Xu Y
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1974. PubMed ID: 38351535
[TBL] [Abstract] [Full Text] [Related]
13. Survival trends and patient characteristics between 2004 and 2016 for breast cancer in Japan based on the National Clinical Database-Breast cancer Registry.
Iwamoto T; Kumamaru H; Niikura N; Sagara Y; Miyashita M; Konishi T; Sanuki N; Tanakura K; Nagahashi M; Hayashi N; Yoshida M; Watanabe C; Kinukawa N; Toi M; Saji S
Breast Cancer; 2024 Mar; 31(2):185-194. PubMed ID: 38319565
[TBL] [Abstract] [Full Text] [Related]
14. Cuproptosis-related genes predict prognosis and trastuzumab therapeutic response in her2-positive breast cancer.
Sha R; Dong X; Yan S; Dai H; Sun A; You L; Guo Z
Sci Rep; 2024 Feb; 14(1):2908. PubMed ID: 38316885
[TBL] [Abstract] [Full Text] [Related]
15. Prediction of Disease-Free Survival in Breast cancer using Deep Learning with Ultrasound and Mammography: A Multicenter Study.
Han J; Hua H; Fei J; Liu J; Guo Y; Ma W; Chen J
Clin Breast Cancer; 2024 Apr; 24(3):215-226. PubMed ID: 38281863
[TBL] [Abstract] [Full Text] [Related]
16. Axillary lymph node dissection in triple-negative or her2-positive breast cancer patients with clinical N2 achieving pathological complete response after neoadjuvant therapy: Is it necessary?
Guo X; Zhang J; Gong X; Wang J; Dai H; Jiao D; Ling R; Zhao Y; Yang H; Liu Y; Liu K; Zhang J; Mao D; He J; Yu Z; Liu Y; Fu P; Wang J; Jiang H; Zhao Z; Tian X; Cao Z; Wu K; Song A; Jin F; Fan Z; Liu Z
Breast; 2024 Feb; 73():103671. PubMed ID: 38277714
[TBL] [Abstract] [Full Text] [Related]
17. Association between postoperative pathological results and non-sentinel nodal metastasis in breast cancer patients with sentinel lymph node-positive breast cancer.
Dong L; Wei S; Huang Z; Liu F; Xie Y; Wei J; Mo C; Qin S; Zou Q; Yang J
World J Surg Oncol; 2024 Jan; 22(1):30. PubMed ID: 38268018
[TBL] [Abstract] [Full Text] [Related]
18. thyroid Ultrasound Image Database and Marker Mask Inpainting Method for Research and Development.
Li X; Fu C; Xu S; Sham CW
Ultrasound Med Biol; 2024 Apr; 50(4):509-519. PubMed ID: 38267314
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy and safety of first-line therapy in patients with her2-positive advanced breast cancer: a network meta-analysis of randomized controlled trials.
Wang J; Yu Y; Lin Q; Zhang J; Song C
J Cancer Res Clin Oncol; 2024 Jan; 150(1):21. PubMed ID: 38244085
[TBL] [Abstract] [Full Text] [Related]
20. Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients.
Guo L; Cheng H; Liu J; Shao W; Luo L; Zheng W; Sun S; Kong D; Chen C
BMC Med Genomics; 2024 Jan; 17(1):25. PubMed ID: 38243282
[TBL] [Abstract] [Full Text] [Related]
[Next]
